CA-QUANTA-CLOUD-TECH
26.8.2021 15:02:11 CEST | Business Wire | Press release
Quanta Cloud Technology (QCT), a leading data center hardware solution provider, today announced details around its participation at the Big 5G Event 2021 , being held onsite as well as virtually from August 30 – September 3, at the Colorado Convention Center, Denver. QCT will showcase 5G demos and solutions developed alongside ecosystem partners (Intel, Red Hat, Robin.io, Wind River, DZS) at Booth #900a for both public and private networks and share their latest insights at the event.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210826005348/en/
QCT 5G Demos, Solutions, and Partner Highlights at the Big 5G Event:
QCT 5G solutions span data center and edge, to on-premise, with two major product lines, IronInfra and OmniPOD , to address infrastructure modernization and digital transformation needs.
-
IronInfra Product Line
: QCT provides IronCloud and IronEdge solutions for telecom infrastructures.
-
IronCloud - Network Function Virtualization Infrastructure (NFVI) solutions for telecom operators. QCT IronCloud provides cloud native infrastructures for mobile network operators running 5G core, vRAN, CNFs, and CDN use cases through its ecosystem partnerships.
-
IronEdge - QCT’s edge solutions that have been approved by the Telecom Infra Project for building and supporting Open RAN in different scenarios, including Centralized RAN, Distributed RAN and MEC use cases.
-
-
OmniPOD Product Line
: End-to-end enterprise 5G network solutions that help achieve the realization of dynamic 5G applications and services.
-
OmniCore : QCT’s cloud-native, virtualized 5G core network solution that features high-availability designs to meet reliability demands and allows for the optimization of network functions.
-
OmniRAN : QCT’s 5G RAN solution consisting of BBU, FHGW, and RRU with flexible system configurations to fulfill diverse coverage and capacity needs.
-
OmniView : QCT’s Operations Administration and Management (OAM) system to manage and monitor OmniCore and OmniRAN.
-
-
Ecosystem Partner Highlights
: Developments alongside the following partners will be on-hand.
-
Intel/Red Hat : QCT builds an Open RAN CU/DU with Red Hat OpenShift, Intel FlexRAN and OpenNESS operator. It achieves automation of installation and configuration and allows easy resource management and monitoring for operators.
-
Robin.io : QCT and Robin.io developed an open and extensible cloud-native automation platform for deployment and lifecycle management of the entire 5G stack, both VNF and CNF with industry leading TCO.
-
Wind River : As a first wave partner to the Wind River Studio Hardware Ready Program, QCT completed self-validation with data center and edge servers which benefit service providers in quickly reducing OPEX while accelerating the introduction of new high-value services.
-
DZS : The QCT and DZS Converged Edge Cloud Blueprints provide simple, easy-to-deploy, jointly validated reference configurations of hardware and software for 5G network services and deployments across the Core, RAN, and Edge Access domains.
-
QCT experts will be available at Booth #900a to share their 5G journey and deployments for multiple customer POCs across industry verticals such as manufacturing, agriculture, and entertainment. Learn more at: https://go.qct.io/telco/
About Quanta Cloud Technology (QCT)
Quanta Cloud Technology (QCT) is a global data center solution provider that combines the efficiency of hyperscale hardware with infrastructure software from a diversity of industry leaders to solve next-generation data center design and operational challenges. QCT serves cloud service providers, telecoms and enterprises running public, hybrid and private clouds.
Product lines include hyperconverged and software-defined data center solutions as well as servers, storage, switches and integrated racks with an ecosystem of hardware components and software partners. QCT designs, manufactures, integrates and services its offerings via its own global network. The parent of QCT is Quanta Computer, Inc., a Fortune Global 500 corporation. www.QCT.io
View source version on businesswire.com: https://www.businesswire.com/news/home/20210826005348/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom